PSY22 ANALYSING THE BENEFITS AND COST SAVING OF ORAL VERSUS IV FLUDARABINE FOR MANAGEMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
May 1, 2011, 00:00
10.1016/j.jval.2011.02.355
https://www.valueinhealthjournal.com/article/S1098-3015(11)00494-3/fulltext
Title :
PSY22 ANALYSING THE BENEFITS AND COST SAVING OF ORAL VERSUS IV FLUDARABINE FOR MANAGEMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00494-3&doi=10.1016/j.jval.2011.02.355
First page :
A63
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
916